RJFSA
OLMA icon

Raymond James Financial Services Advisors’s Olema Pharmaceuticals OLMA Stock Holding History

Raymond James Financial Services Advisors’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-13,287
Closed -$164K – 3390
2023
Q3 		$164K Buy
+13,287
New +$135K ﹤0.01% 2982

Other funds holding OLMA

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Raymond James Financial Services Advisors's OLMA Position: Q4 2023 in Review

Raymond James Financial Services Advisors sold out of Olema Pharmaceuticals (OLMA) in Q4 2023, closing a stake of 13,287 shares — an estimated $164K sold.

Raymond James Financial Services Advisors first reported a position in OLMA in Q3 2023 and held it in 1 quarter. The position peaked at $164K in Q3 2023. 113 funds tracked by Wall St. Rank hold OLMA as of Q4 2023.

  • Raymond James Financial Services Advisors reported no remaining Olema Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 13,287 Olema Pharmaceuticals shares in Q4 2023, an estimated $164K.
  • Raymond James Financial Services Advisors first reported a position in Olema Pharmaceuticals in Q3 2023 and held it in 1 quarter.
  • Raymond James Financial Services Advisors's Olema Pharmaceuticals position peaked at $164K in Q3 2023.
  • 113 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q4 2023.

Based on Raymond James Financial Services Advisors's 13F filing for Q4 2023, filed 16 Jan 2024.